Psyadon Pharmaceuticals, Inc., a company focused on treatments for neurological and psychiatric disorders, announced today that its lead product -- ecopipam -- produced significant reductions in total tic severity scores in children (7-17 years) with Tourette’s Syndrome.
The study’s primary endpoint was a statistically significant reduction in the mean Yale Global Tic Severity Score Total Tic Score (YGTSS-TTS). This is a well-validated and standard measure of the clinical efficacy of drugs treating Tourette’s Syndrome. Ecopipam caused significant reductions in the YGTSS-TTS at both two- and four weeks after initiating treatment. Furthermore, the side effects seen in the subjects taking ecopipam were comparable to those seen in the placebo-treated subjects, including no clinically significant changes in standard clinical lab tests or ECG’s, and no increases in body weights.